Patents by Inventor Sae Gwang Park

Sae Gwang Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vascular endothelial growth factor receptor targeting peptide-elastin fusion polypeptides
    Patent number: 11518798
    Abstract: Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: December 6, 2022
    Assignees: Industry-University Cooperation Foundation Hanyang University Erica Campus, Inje University Industry-Academic Cooperation Foundation
    Inventors: Dong Woo Lim, Min Jung Kang, Jae Sang Lee, Sae-Gwang Park
  • VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TARGETING PEPTIDE-ELASTIN FUSION POLYPEPTIDES AND THEIR SELF-ASSEMBLED NANOSTRUCTURES
    Publication number: 20200331986
    Abstract: Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.
    Type: Application
    Filed: April 20, 2020
    Publication date: October 22, 2020
    Applicants: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS, INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Dong Woo LIM, Min Jung KANG, Jae Sang LEE, Sae-Gwang PARK
  • Vascular endothelial growth factor receptor targeting peptide-elastin fusion polypeptides
    Patent number: 10662236
    Abstract: Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: May 26, 2020
    Assignees: Industry-University Cooperation Foundation Hanyang University Erica Campus, Inje University Industry-Academic Cooperation Foundation
    Inventors: Dong Woo Lim, Min Jung Kang, Jae Sang Lee, Sae-Gwang Park
  • VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TARGETING PEPTIDE-ELASTIN FUSION POLYPEPTIDES AND THEIR SELF-ASSEMBLED NANOSTRUCTURES
    Publication number: 20180208642
    Abstract: Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.
    Type: Application
    Filed: October 19, 2016
    Publication date: July 26, 2018
    Applicants: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS, INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Dong Woo LIM, Min Jung KANG, Jae Sang LEE, Sae-Gwang PARK
  • COMPOSITION FOR IMPROVING RADIOTHERAPY FOR CANCER
    Publication number: 20110250292
    Abstract: Disclosed is a composition for improving radiotherapy for cancer, containing tetra-arsenic oxide (As4O6) as an active ingredient. The disclosed composition for improving radiotherapy for cancer improves the efficiency of radiotherapy, and thus reduces side effects caused by the high-dose radiation. The disclosed composition uses tetra-arsenic oxide, the safety of which is proven, from among conventional arsenic compound derivatives, to prevent side effects caused by arsenic trioxide, taxol, cisplatin, fluorouracil, leuprolide, or the like, which are known as conventional radiosensitizers.
    Type: Application
    Filed: November 30, 2009
    Publication date: October 13, 2011
    Applicant: CHONJISAN CO., LTD.
    Inventors: Ill Ju Bae, Sae Gwang Park